Donna Wray, TGAS ADVISORS
In other industries, online marketing is used to cycle through options quickly and dynamically to reach an optimal solution.
Donna Wray
MANAGEMENT ADVISOR, LEADER OF INTERNET AND RELATIONSHIP MARKETING PRACTICE | TGAS ADVISORS
In other industries, online marketing is used to cycle through options quickly and dynamically to reach an optimal solution and stay there over time and through changing market conditions. A/B testing, where two versions of an ad are compared, has changed to ABCDE, etc., testing online, since it is easy to quickly change copy or creative and see how targets' actions change. Pharma is certainly more limited in being able to change and then launch copy quickly, but it could do more of this by getting several simple alternatives approved in place of one.
Donna Wray
I observed a focus group where the person being interviewed was 30 years old, out of work, and not taking his blood pressure medication because he felt guilty using that money on himself instead of his family. I felt terrible. I wanted to shout at him, "What will happen if you need a new kidney because you haven't taken your medication? What will that cost your family!" Pharma marketers are prohibited from such extreme statements, but people need to understand that the risks and costs of not being treated are far greater for many conditions, even if they are asymptomatic.
It's clear that paid search investment and leads will drop dramatically across the industry. Other online promotion can use that budget, although not as efficiently. Nonetheless, increasing display advertising is likely to be important in order to compensate for the lack of voice of pharma brands to reach people looking for treatment information online.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.
